logo

For the Inventor, By the Inventor

Ludwigshafen, Germany

Phenex Pharmaceuticals Ag


USPTO Granted Patents = 11



Forward Citations = 96

Loading Chart...
Loading Chart...

27 inventors (with patents filed for the assignee):

goldMedal Christoph Steeneck (8 out of 23 patents)

silverMedal Thomas Hoffmann (7 out of 13 patents)

bronzeMedal Olaf Kinzel (6 out of 22 patents)

4.  Gerald Kleymann (5 out of 18 patents)

5.  Claus Kremoser (5 out of 16 patents)

6.  Ulrich Deuschle (5 out of 9 patents)

7.  Christian Gege (4 out of 36 patents)

8.  Michael Albers (3 out of 3 patents)

9.  Ulrich Abel (2 out of 15 patents)

10.  Kerstin Otte (2 out of 7 patents)

11.  Elena Dneprovskaia (2 out of 11 patents)

12.  Ulrike Bauer (2 out of 3 patents)

13.  Zach Cheruvallath (2 out of 3 patents)

14.  Tim Gahman (2 out of 3 patents)

15.  Kristina Giegrich (2 out of 3 patents)


11 patents:

1. 11376241 - Aryl hydrocarbon receptor (AhR) modulator compounds (2022-07-05),
2. 10981908 - Aryl hydrocarbon receptor (AHR) modulator compounds (2021-04-20),
3. 10301272 - Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ] (2019-05-28),
4. 9815851 - Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases (2017-11-14),
5. 9458104 - Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor RORγ (2016-10-04),
6. 8952042 - FXR (NR1H4) binding and activity modulating compounds (2015-02-10),
7. 8946446 - Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-γ (ROR-γ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases (2015-02-03),
8. 8940722 - Compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune disease (2015-01-27),
9. 8193192 - Heterocyclic FXR binding compounds (2012-06-05),
10. 7098336 - FXR NR1H4 nuclear receptor binding compounds (2006-08-29),
11. 7034046 - NR1H4 nuclear receptor binding compounds (2006-04-25),
PHENEX PHARMACEUTICALS AG is a biopharmaceutical company focused on the research and development of innovative therapies for liver diseases. With a strong emphasis on liver fibrosis, the company aims to provide effective treatments addressing unmet medical needs. PHENEX PHARMACEUTICALS AG combines expertise in drug discovery, clinical development, and regulatory affairs to bring novel therapies to patients.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

11 Patents

#20 in Ludwigshafen

#3,500 in Germany

#50,238 in the World

...
Ludwigshafen, Germany

Phenex Pharmaceuticals Ag

Forward Citations = 96

27 inventors:

goldMedal Christoph Steeneck (8 out of 23 patents)

silverMedal Thomas Hoffmann (7 out of 13 patents)

bronzeMedal Olaf Kinzel (6 out of 22 patents)

4.  Gerald Kleymann (5 out of 18 patents)

5.  Claus Kremoser (5 out of 16 patents)

Please report any incorrect information to support@idiyas.com
Loading…